• 1. Tianjin Taicheng Yaozhong Biomedical Technology Co., Ltd., Tianjin, 300193, P.R.China;
  • 2. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, P.R.China;
  • 3. School of Chinese Medicine, HongKong Baptist University, Hongkong, 999077, P.R.China;
  • 4. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
SHANG Hongcai, Email: shanghongcai@foxmail.com
Export PDF Favorites Scan Get Citation

In recent years, CRO has developed rapidly in China, and has played an important role in improving the level of Chinese clinical trials and drug development. However, the development of CRO industry also has problems. This paper discusses the beneficial factors of the main problems and the future direction of CRO, in attempt to attract the attention of government supervision and management departments and CRO industries.

Citation: LEI Xiang, WANG Xiaohui, LI Jing, WANG Bei, ZHAO Chen, YU Jiajie, LI Youping, WU Taixiang, BIAN Zhaoxiang, SHANG Hongcai. Development and changes of CRO of clinical trials in China. Chinese Journal of Evidence-Based Medicine, 2018, 18(8): 783-786. doi: 10.7507/1672-2531.201804083 Copy

  • Previous Article

    Development and changes of quality control of clinical trials in China
  • Next Article

    Development and changes of clinical practice guidelines in China